A metalloproteinase inhibitor prevents lethal acute graft-versus-host disease in mice

Blood

Volumn 90, Issue 2, 1997, Pages 542-548

  Hattori, Koichi ^b   Hirano, Takao ^b   Ushiyama, Chifuyu ^b   Miyajima, Hiroaki ^b   Yamakawa, Norifumi ^b   Ebata, Tomohiko ^b   Wada, Yukihisa ^b   Ikeda, Shoji ^b   Yoshino, Kohichiro ^b   Tateno, Masatoshi ^b   Oshimi, Kazuo ^b   Kayagaki, Nobuhiko ^b   Yagita, Hideo ^b   Okumura, Ko ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; KB R 7785; METALLOPROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; WEIGHT REDUCTION;

EID: 0030854908     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.2.542.542_542_548     Document Type: Article

References (33)

1. Martin PJ, Hansen JA, Storb R, Thomas ED: Human marrow transplantation: An imunological perspective. Adv Immunol 40:379, 1987
2. Herve P, Cahn JY, Beatty PG: Graft-versus-host disease after bone marrow transplantation from donors other than HLA-identical siblings, in Burakoff SJ, Deeg HJ, Ferrara J, Atkins K (eds): Graft-Versus-Host Disease. New York, NY, Dekker, 1990, p 425
3. Gleichemann E, Pals ST, Rolink AG, Radaszkiewics T, Gleichmann H: Graft-versus-host reactions: Clues to the etiopathology of a aspectrum of immunological diseases. Immunol Today 5:324, 1984
4. Tracey KJ, Wei H, Manogue KR, Fong Y, Hesse DG, Nguyen HT, Kuo GC, Beutler B, Cotran, RS, Cerami A, Lowry SF: Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med 167:1211, 1988
5. Vassalli P: The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10:411, 1992
6. Holler E, Kolb HJ, Möller A, Kempeni J, Loesenfeld S, Pechumer H, Lemacher W, Ruckdeschel G, Gleixner B, Riedner C: Increased serum levels of tumor necrosis factor a precede major complications of bone marrow transplantation. Blood 75:1011, 1990
7. Piguet PF, Grau GE, Allet B, Vassalli P: Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs-host disease. J Exp Med 166:1280, 1987
8. Hervé P, Flesch M, Tiberghien P, Wijdenes J, Racadot E, Bordigoni P, Plouvier E, Stephan JL, Bourdeau H, Holler E, Lioure B, Roche C, Vilmer E, Demeocq F, Kuentz M, Chan JY: Phage I-II trial of a monoclonal anti-tumor necrosis factor a antibody for the treatment of refractory severe acute graft-versus host disease. Blood 79:3362, 1992
9. Nagata S, Golstein P: The Fas death factor. Science 267:1449, 1995
10. Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Brüderlein S, Henne C, Schmidt A, Debatin K-M, Krammer PH, Möller P: Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69:415, 1993
11. Baker MB, Altman NH, Podack ER, Levy RB: The role of cell-mediated cytotoxicity in acute GVHD after MHC-mached allogeneic bone marrow transplantation in mice. J Exp Med 183:2645, 1996
12. Braun MY, Lowin B, French L, Acha-Orbea H, Tschopp J: Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolyric activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 183:657, 1996
13. Smith CA, Farrah T, Goodwin RG: The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death. Cell 76:959, 1994
14. Gearing AJH, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, Leber TM, Mangan M, Miller K, Nayee P, Owen K, Patel S, Thomas W, Wells G, Wood LM, Woolley K: Processing of tumor necrosis factor-α precursor by metalloproteinases. Nature 370:555, 1994
15. McGeehan GM, Becherer JD, Vast RC Jr, Boyer CM, Champion B, Connolly KM, Conway JG, Furdon P, Karp S, Kidao S, McElroy AB, Nichols J, Pryzwansky KM, Schoenen F, Sekut L, Truesdale A, Verghese M, Warner J, Ways JP: Regulation of tumor necrosis factor-α processing by a metalloproteinase inhibitor. Nature 370:558, 1994
16. Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Alderson M, Kerwar SS, Torrance DS, Otten-Evans C, Greenstreet T, Weerawarna K, Kronheim SR, Peterson M, Gerhart M, Kozlosky CJ, March CJ, Black RA: Protection against a lethal dose of endotoxin by an inhibitor of tumor necrosis factor processing. Nature 370:218, 1994
17. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H: Metalloproteinase-mediated release of human Fas ligand. J Exp Med 182:1777, 1995
18. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S: Fas ligand in human serum. Nat Med 2:317, 1996
19. Hirayama R, Yamamoto M, Tsukida T, Matsuno K, Obata Y, Sakamoto F, Ikeda S: Synthesis and biological evalution of orally active matrix metalloproteinase inhibitors. Bioorg Med Chem (in press)
20. Broxmeyer HE, Williams DE, Lu L, Cooper S, Anderson SL, Beyer GS, Hoffman R, Rubin BY: The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia. Synergism of tumor necrosis factor and interferon-γ. J Immunol 136:4487, 1986
21. Murphy M, Perussia B, Trinchieri G: Effects of recombinant tumor necrosis factor on the colony growth of human leukemia progenitor cells and normal hematopoietic progenitor cells. Blood 69:467, 1988
22. Jacobson FW, Rothe M, Rusten L, Goeddel DV, Smeland EB, Veiby OP, Slørdal L, Jacobson SEW: Role of the 75-kDa tumor necrosis factor receptor: Inhibition of early hematopoiesis. Proc Natl Acad Sci USA 91:10695, 1994
23. Charles SV, Nguyen P, Shustov A, Drappa J, Elkon KB: A major role for the fas pathway in acute graft-versus-host disease. J Immunol 157:5387, 1996
24. Baker MB, Riley RL, Podack ER, Levy RB: Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perform function. Proc Natl Acad Sci USA 94:1366, 1997
25. Dhein J, Walczak H, Bäumler C, Debatin KM, Krammer PH: Autocline T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373:438, 1995
26. Perez C, Albert I, DeFay K, Zachariades N, Gooding L, Kriegler M: A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 63:251, 1990
27. + T cell clones provies a costimulatory signal for human B cell activation. J Exp Med 177:1575, 1993
28. Grell M, Douni F, Wajant H, Löhden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K, Scheurich P: The transmembrane form of tumor necrosis factor is the prime acrivating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83:793, 1995
29. Hanabuchi S, Koyanagi M, Kawasaki A, Shinohara N, Matsuzawa A, Nishimura Y, Kobayashi Y, Yonehara S, Yagita H, Okumura K: Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. Proc Natl Acad Sci USA 91:4930, 1994
30. Pender SLF, Tickle SP, Dolcherty AJP, Howie D, Wathen NC, MacDonald TT: A major role for matrix metalloproteinase in T cell injury in the gut. J Immunol 158:1582, 1997
31. Harris J, Langleben A, Casper E, Allen R, Rasmussen H: Marimastat, a novel matrix metalloproteinase inhibitor in patients with advanced carcinoma of the pancreas. Proc Am Soc Clin Oncol 15:207, 1996 (abstr 470)
32. Boasberg P, Harbaugh H, Roth B, Eisenherger M, Langleben A, Allen R, Rasmussen H: Marimastat, a novel matrix metalloproteinase inhibitor in patients with hormone-refractory prostate cancer. Proc Am Soc Clin Oncol 15:258, 1996 (abstr 671)
33. Malfetano J, Teng N, Moore D, Barter J, Lopez A, Schink J, Cole A, Rasmussen H: Marimastat, a novel matrix metalloproteinase inhibitor in patients with advanced cancer of the ovary. Proc Am Soc Clin Oncol 15:283, 1996 (abstr 764)